Equillium — Third Quarter 2026 Earnings Summary

Equillium, Inc. initiated a Phase 1 clinical trial for its investigational drug EQ504 in October 2026, with proof-of-mechanism data expected in the second quarter of 2027. The company reported cash and cash equivalents of $53.3 million as of September 30, 2026, and secured an additional $20 million in financing later that month, extending its cash runway into 2029. For the third quarter of 2026, Equillium recorded a net loss of $4.6 million, driven by research and development expenses of $2.5 million and general and administrative expenses of $2.6 million. EQ504 is a selective aryl hydrocarbon receptor modulator designed to treat ulcerative colitis and other inflammatory disorders through a non-immunosuppressive mechanism.